Publications by authors named "Keith Pratz"

Claim this Profile
A
Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1.
Keith W Pratz

Br J Haematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen.
Margaret Rowe, Daria Babushok, Martin Carroll, Alison Carulli, Noelle Frey, Keith Pratz

Eur J Haematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frontline Therapy of AML in the Fit and Younger Population-Incorporating Molecularly Targeted Agents.
Keith W Pratz, Harry P Erba

Am J Hematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia.
Vinod Pullarkat, Keith W Pratz, Hartmut Döhner, Christian Recher, Michael J Thirman

Blood Cancer J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolving racial/ethnic disparities in AML survival in the novel therapy era.
Xin Wang, Phyllis A Gimotty, Andrew H Matthews, Ronac Mamtani, Selina M Luger, Keith W Pratz

Blood Adv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia.
Courtney D DiNardo, Keith W Pratz, Panayiotis Panayiotidis, Xudong Wei, Vladimir Vorobyev

Am J Hematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.
Hartmut Döhner, Keith W Pratz, Courtney D DiNardo, Andrew H Wei, Brian A Jonas

Blood· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Ven the dose matters: Venetoclax dosing in the frontline treatment of AML.
Dahniel Sastow, Hannah Levavi, Nicole Wagner, Keith Pratz, Douglas Tremblay

Blood Rev· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia.
Matthew P Connor, Neeharika Prathapa, Noelle V Frey, Saar I Gill, Elizabeth O Hexner, Keith W Pratz

Haematologica· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of an Approach to Equitable Allocation of SARS-CoV-2 Monoclonal Antibodies for Preexposure Prophylaxis: Experience From a Single Medical Center.
Keith W Hamilton, Elvis Hua, Lauren Dutcher, Holly Fernandez Lynch, Paul Junker, Keith Pratz

Open Forum Infect Dis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
Mark R Litzow, Zhuoxin Sun, Ryan J Mattison, Elisabeth M Paietta, Kathryn G Roberts, Keith W Pratz

N Engl J Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.
Anthony D Sung, Thuy Koll, Shannon H Gier, Alessandro Racioppi, Griffin White, Keith W Pratz

Transplant Cell Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Keith W Pratz, Brian A Jonas, Vinod Pullarkat, Michael J Thirman, Jacqueline S Garcia

Am J Hematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CML and the WHO: Why?
Ellin Berman, Neil P Shah, Michael Deninger, Jessica K Altman, Maria Amaya, Keith Pratz

J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Neil P Shah, Ravi Bhatia, Jessica K Altman, Maria Amaya, Kebede H Begna, Keith Pratz

J Natl Compr Canc Netw· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.
Xue Li, Hae Sun Suh, Jean Lachaine, Andre C Schuh, Keith Pratz

Value Health· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
Keith W Pratz, Mohamad Cherry, Jessica K Altman, Brenda W Cooper, Nikolai A Podoltsev

J Clin Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
Rory M Shallis, Naval Daver, Jessica K Altman, Rami S Komrokji, Daniel A Pollyea, Keith W Pratz

Lancet Haematol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
Andrew H Matthews, Alexander E Perl, Selina M Luger, Saar I Gill, Catherine Lai, Keith W Pratz

Am J Hematol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
Keith W Pratz, Jason Kaplan, Moshe Levy, Dale Bixby, Patrick W Burke

Haematologica· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in targeted therapies in acute myeloid leukemia.
Rahul S Bhansali, Keith W Pratz, Catherine Lai

J Hematol Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
Matthew P Connor, Alison W Loren, Elizabeth O Hexner, Mary Ellen Martin, Saar I Gill, Keith W Pratz

Transplant Cell Ther· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing outcomes in secondary AML.
Andrew Matthews, Keith W Pratz

Hematology Am Soc Hematol Educ Program· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
Keith W Pratz, Courtney D DiNardo, Dominik Selleslag, Junmin Li, Kazuhito Yamamoto

Am J Hematol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid Leukemia.
Andrew H Matthews, Keith W Pratz, Martin P Carroll

Cancers (Basel)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis